PD184352 (CI-1040)

Catalog No.S1020

PD184352 (CI-1040) Chemical Structure

Molecular Weight(MW): 478.67

PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 70 In stock
USD 120 In stock
USD 270 In stock
USD 670 In stock
USD 770 In stock

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 43 Publications

12 Customer Reviews

  • The inhibitor PD173074 (A) or PD184352 (B) was administered to one uterine horn of Hand2d/d mice on day 3 of pregnancy (n = 5). The other horn served as vehicle-treated control. Uterine horns were collected on the morning of day 4, and sections were subjected to IHC to detect p-FRS2, p-ERK1/2, and Ki-67. (C) IHC of pERa and Muc-1 in uterine sections of Hand2d/d mice treated with PD173074 or PD184352.

    Science 2011 331, 912-916. PD184352 (CI-1040) purchased from Selleck.

     

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. Western blot analysis for c-Jun, phosphorylated-ERK1/2 (Thr202/Tyr204) (p-ERK1/2), and total ERK1/2 protein levels was done for human melanoma cell lines treated with the BRAFV600E inhibitor GDC-0879 (1 μM), or MEK inhibitors CI-1040 (1 μM), U0126 (1 μM), and PD98059 (10 μM) for 18 hours.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

  •  

    Melanoma cell viability and in vivo growth by cyclindependent kinase 2/4 inhibition. In vivo growth of LOXIMVI xenografts in athymic nude Foxn1nu mice is shown. Tumors were allowed to grow to a maximum volume of 250 mm3, and the mice were subsequently treated daily at the indicated dose levels with CDK2/4 inhibitors by intraperitoneal injection in combination with a BRAFV600E- or MEK-inhibitor. CDK2/4 inhibitor (CVT-313/indolocarbazole CDK4-I) treatment sensitizes tumors to GDC-0879 and CI1040.

    J Natl Cancer Inst 2012 104(21), 1673-9. PD184352 (CI-1040) purchased from Selleck.

    LY294002 (10 μM for 12 h)- and PD184352 (10 μM for 12 h)-treated Her2-transfected DU145 and PC3 cells, respectively, showed reciprocal feedback inhibition between the PI3K/AKT and MEK/ERK path ways

    Proc Natl Acad Sci U S A 2011 108, 16392-7. PD184352 (CI-1040) purchased from Selleck.

  • The effect of CI-1040 on cell viability of molecular apocrine lines. MTT assay to measure cell viability in MDA-MB-453 cell line after treatment with CI-1040 (CI) at 2 to 25 μM concentrations. MTT assay to measure cell viability in HCC-1954 cell line after treatment with CI-1040 at 2 to 25 μM concentrations.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

    Combination indices (CI) for flutamide (FLU) and CI-1040 combination therapy in MDA-MB-453-R line using MTT assay. Therapies were carried out with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM (CI-5 and CL-10). The concentrations of fluatmide and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2SEM. Western blot analysis was used to measure the phosphorylated and total ERK levels in MDA-MB-453-R line following combination therapies with CI-1040 (5 μM)/flutamide (5 μM) and CI-1040 (5 μM)/flutamide (10 μM). RR values were measured relative to the untreated MDA-MB-453-R line.

    Breast Cancer Res 2011 13, R36. PD184352 (CI-1040) purchased from Selleck.

  • Western blot analysis to measure the phosphorylated and total ERK levels in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (CI) at 10-μM concentration.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    Relative expression of AR using RT-PCR in MDA-MB-453 and HCC-1954 cell lines after treatment with CI-1040 (MEK Inh) at 10-μMconcentration for 24 hours. Expression is relative to that of vehicle-treated cells (CTL). *P < .01 is for CI-1040 versus control. Error bars,±2 SEMs.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

  • Synergistic effect of AR and mitogen-activated protein kinase kinase inhibitors on cell viability. (A) MTT assay to measure cell viability in MDA-MB-453 cell line after monotherapies and combination treatments with flutamide (FLU) and CI-1040 (CI) at 5 and 10 μΜ concentrations. CTL: control. Error bars: ±2 SEM. (B) Combination indices (CI) for flutamide and CI-1040 combination therapy in MDA-MB-453 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 5 and 10 μM with each concentration of CI-1040 at 5 and 10 μM. The concentrations of FLU and CI-1040 monotherapies with an effect similar to that of each combination therapy are depicted. Error bars: ±2 SEM. (C) Combination indices for flutamide and CI-1040 combination therapy in HCC-1954 cell line using MTT assay. Cell viability was measured after combination therapies with flutamide at 20 and 40 μM with each concentration of CI-1040 at 5 and 10 μM. (D) Combination indices for flutamide and CI-1040 combination therapy in HCC-202 cell line using MTT assay at concentrations described in Figure 2C.

     

     

    Neoplasia 2011 13, 154–166. PD184352 (CI-1040) purchased from Selleck.

    After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

  • After starved in serum-free medium for 24h, Breast cancer cells incubated with the indicated concentrations of CI-1040 for 3h,followed by 15-minute stimulation of 100ng/ml EGF

     

    2010 Dr. Zhang of Tianjin Medical University. PD184352 (CI-1040) purchased from Selleck.

    The bar chart represents the relative numbers of third-round colonies of primary hematopoietic cells transduced with MLL-AF9 with treatment of compound PD184352 (CI-1040, 10 μM, a MEK inhibitor) and SB216763 (10 μM, GSK-3 inhibitor). The synergic effect between compounds CI-1040 and SB-216763 has been observed.

     

     

    2010 Dr. Shuo Dong of Baylor College of Medicine. PD184352 (CI-1040) purchased from Selleck.

Purity & Quality Control

Choose Selective MEK Inhibitors

Click to view more

Notes:

2. For more details, such as half maximal inhibitory concentrations (IC50s) and working concentrations of each inhibitor, please click on the link of the inhibitor of interest.
3. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation.
4. Orange "√" refers to compounds which do inhibitory effects on the related isoform, but without specific value.

Biological Activity

Description PD184352 (CI-1040) is an ATP non-competitive MEK1/2 inhibitor with IC50 of 17 nM in cell-based assays, 100-fold more selective for MEK1/2 than MEK5. Phase 2.
Features First MEK inhibitor to begin clinical development.
Targets
MEK1 [1]
(Cell-free assay)
MEK2 [1]
(Cell-free assay)
17 nM 17 nM
In vitro

CI-1040 treatment produces a reduction of pMAPK levels in multiple tumor cells including Colon 26, BX-PC3 pancreatic, A431 cervical, HT-29 colon, ZR-25-1 breast and SKOV-3 ovarian carcinomas. CI-1040 treatment doesn't inhibit the phosphorylation of Jun kinase, p38 kinase or Akt, indicating CI-1040 specifically targets MEK. Inhibition of MAPK activation by CI-1040 prevents cell cycle progression and induces a G1 block. [1] The IC50 for inhibition of MEK1 by CI-1040 is 0.3 μM, 15-fold higher than the concentration required to inhibit the EGF-induced activation of ERK2 in Swiss 3T3 cells. These results indicate CI-1040 exerts its effects on cells by suppressing the activation of MKK1, and not by blocking its activity. 2 nM PD184352 inhibits the activation of MKK1 in Swiss 3T3 cells by 50%, while over 100-fold concentration of CI-1040 inhibits MEK1 in vitro. PD184352 also inhibits the Raf-catalysed phosphorylation of MEK1 without any effect on the Raf-catalysed phosphorylation of myelin basic protein. [2] CI-1040 inhibits 86% of papillary thyroid carcinoma (PTC) cell growth with the RET/PTC1 rearrangement at 10μM compared with cells treated with DMSO only. CI-1040 shows potent inhibition to PTC cells (BRAF mutation) with GI50 of 52 nM, but low activity to RET/PTC1 rearrangement type with GI50 of 1.1 μM. [3] A recent research indicates CI-1040 increases the apoptotic effect of BMS-214662 in a CML blast crisis cell line, K562, and in primary chronic phase CD34+ CML cells. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
H9 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mk[5TWM2OD1yLkCyNlc3KM7:TR?= MnTMV2FPT0WU
CHP-212 NXvw[nVtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTBwMEK4PFUh|ryP MmPoV2FPT0WU
EoL-1-cell MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37u[WlEPTB;MD6wOFE2OiEQvF2= NYD1dXZFW0GQR1XS
DU-4475 NGLVTWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rvO2lEPTB;MD6wO|U6QSEQvF2= NXLHUoN5W0GQR1XS
MMAC-SF NEjMVYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVvBSm1XUUN3ME2wMlExQTd2IN88US=> Mlf3V2FPT0WU
AGS M4rpeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1LGWGlEPTB;MD6xNVcyOyEQvF2= MnXUV2FPT0WU
M14 NHewNldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXl[29mUUN3ME2wMlE2PDZ6IN88US=> NGLjbHFUSU6JRWK=
CP50-MEL-B NHPJZY1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlToTWM2OD1yLkG3NlU1KM7:TR?= NEiyS3JUSU6JRWK=
C32 MkXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnoWHNIUUN3ME2wMlE6ODd{IN88US=> M1TS[3NCVkeHUh?=
KMOE-2 NIrEWFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrTT2NKSzVyPUCuNVk4QTVizszN M2OxR3NCVkeHUh?=
A101D MlW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2HQcGlEPTB;MD6yNVQh|ryP MnHkV2FPT0WU
KM12 M{T0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n5[mlEPTB;MD6yOFA2PyEQvF2= M3zsO3NCVkeHUh?=
HSC-4 NGHwflRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjxTWM2OD1yLkK0N|k2KM7:TR?= MUfTRW5ITVJ?
NOMO-1 NELBXZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGjNTpVKSzVyPUCuNlU4PDJizszN NH\1O3dUSU6JRWK=
MZ7-mel NE\hWo5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHTPWWhKSzVyPUCuNlY{PCEQvF2= MnGxV2FPT0WU
ACN MlHVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTBwMk[3N|ch|ryP NVHIW25MW0GQR1XS
MEL-HO Mlm5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHnOWJVKSzVyPUCuNlc3PTJizszN M4DXeHNCVkeHUh?=
BHT-101 MnHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nmdGlEPTB;MD6yPFYxPiEQvF2= M1rObHNCVkeHUh?=
SK-MEL-28 Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwM{C0NFkh|ryP NVHyTIg2W0GQR1XS
KG-1 NWfOTIlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PWXGlEPTB;MD6zNFY3QCEQvF2= M{DO[nNCVkeHUh?=
COLO-679 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILpd29KSzVyPUCuN|I4OiEQvF2= MknhV2FPT0WU
SK-MEL-24 M3u3cWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3reJFKSzVyPUCuN|I5OTNizszN MYfTRW5ITVJ?
G-361 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M36xR2lEPTB;MD6zOlc6PSEQvF2= M4TPVXNCVkeHUh?=
KY821 MljjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvuV2MzUUN3ME2wMlM4QTFizszN MmTBV2FPT0WU
KASUMI-1 MoexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;jTWM2OD1yLkO5PUDPxE1? NILHOI5USU6JRWK=
HL-60 MmnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXjTlNJUUN3ME2wMlQyOTB5IN88US=> NVfXcZVmW0GQR1XS
K5 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDkUZRKSzVyPUCuOFMyOTdizszN NH:zNItUSU6JRWK=
KU812 MlP4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXIbWZpUUN3ME2wMlQ2Ojl7IN88US=> M{W1[XNCVkeHUh?=
SH-4 NIXiS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXHJR|UxRTBwNE[yOVYh|ryP NG\Ne21USU6JRWK=
HTC-C3 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrJNpk5UUN3ME2wMlQ3PTNzIN88US=> NEXDT25USU6JRWK=
CP66-MEL M4Lhe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoPLTWM2OD1yLkS4PFA6KM7:TR?= MnTNV2FPT0WU
WM-115 NGG5THpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1u3eGlEPTB;MD60PVI2PyEQvF2= NWG0ZmVGW0GQR1XS
A2780 M1XhV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3G5NmlEPTB;MD60PVgzOyEQvF2= M33NWXNCVkeHUh?=
P12-ICHIKAWA MnTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEDGXnRKSzVyPUCuOlEzOjFizszN NYThU|FuW0GQR1XS
HMV-II MoLDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7VTWM2OD1yLk[0OFY2KM7:TR?= NVS5b4xwW0GQR1XS
HT-144 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\0XFBKSzVyPUCuOlQ3PTdizszN NY\pbldYW0GQR1XS
LB2518-MEL MoX2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYTEZmRbUUN3ME2wMlcyPjN{IN88US=> MnK2V2FPT0WU
NCI-SNU-1 NIHacW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwN{W0N|Mh|ryP MnHXV2FPT0WU
C2BBe1 NHPXPI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTBwOEGwNlMh|ryP M{CwOXNCVkeHUh?=
PSN1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3YelJKSzVyPUCuPVYyQTZizszN MkLNV2FPT0WU
UACC-257 MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;ETWM2OD1yLkm2OFc{KM7:TR?= M4DvOHNCVkeHUh?=
RVH-421 MlP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{KxNWlEPTB;MD65O|E5KM7:TR?= NH;vVlRUSU6JRWK=
GP5d NY\KfXVJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\sTWM2OD1yLkm4N|A5KM7:TR?= NV;mbWpSW0GQR1XS
TYK-nu NUP3eYhbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTFwMEOxO|Ih|ryP MX\TRW5ITVJ?
SK-N-AS M4LUWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUj6OHQ5UUN3ME2xMlA4QTR5IN88US=> M{f1O3NCVkeHUh?=
SW620 NYnke|BsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo\jTWM2OD1zLkGzOVM1KM7:TR?= MVzTRW5ITVJ?
HuP-T4 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnfOTWM2OD1zLkG4N|U6KM7:TR?= NVrzfpFkW0GQR1XS
A549 M1XRT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;YfGlEPTB;MT6xPVU4PiEQvF2= NX35eVlCW0GQR1XS
Mewo MmiwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DKS2lEPTB;MT6yNFI4PiEQvF2= MWPTRW5ITVJ?
ONS-76 NHXaN|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIG3OWtKSzVyPUGuNlIxPDlizszN NFnVd2RUSU6JRWK=
SK-MEL-1 MlXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFwMkO0NVkh|ryP NFXlZ2VUSU6JRWK=
RCM-1 NHL1VGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnL3TWM2OD1zLkK0NFQ4KM7:TR?= M1O4OnNCVkeHUh?=
H-EMC-SS MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTFwMkm2NFgh|ryP NXnDXIpVW0GQR1XS
NCI-H2291 NELkdldIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvOTWM2OD1zLkOyOVM3KM7:TR?= MWPTRW5ITVJ?
SW1463 M33IfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGT0WJdKSzVyPUGuN|M4OjFizszN NH;XOFlUSU6JRWK=
LS-411N M{DwV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWC2UmNOUUN3ME2xMlQxPTF5IN88US=> M3Sx[nNCVkeHUh?=
BV-173 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnwbZJpUUN3ME2xMlQ1ODF3IN88US=> M3\YW3NCVkeHUh?=
LS-513 M3f3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\NfWlEPTB;MT60OVE6OiEQvF2= M17WdXNCVkeHUh?=
LoVo NULKflQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXzTWM2OD1zLkS2N|k6KM7:TR?= NEHyWY9USU6JRWK=
HO-1-N-1 M{LiV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi0RXdKSzVyPUGuOVE3OzRizszN NVOwXIYxW0GQR1XS
ML-2 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXiTWM2OD1zLkWyPFY5KM7:TR?= MWPTRW5ITVJ?
NCI-H1437 MkTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zENWlEPTB;MT61OVI4PSEQvF2= MYrTRW5ITVJ?
SW1116 NUXXOppCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nXNmlEPTB;MT61OlM6QCEQvF2= MljSV2FPT0WU
A4-Fuk NYLYN5IyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2S0V2lEPTB;MT61O|A1PSEQvF2= MXnTRW5ITVJ?
HD-MY-Z NXPDOVhVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1u5cGlEPTB;MT61O|M4PiEQvF2= MYHTRW5ITVJ?
SK-MEL-2 M{PKOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjqRpJFUUN3ME2xMlU4PDV7IN88US=> MlT2V2FPT0WU
RT-112 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfzeoJKSzVyPUGuOVg6PTJizszN M2LVfnNCVkeHUh?=
COLO-829 M2Tpemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIH0XpdKSzVyPUGuOlIzOzJizszN MXHTRW5ITVJ?
OVCAR-5 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH5TWM2OD1zLke3Olg4KM7:TR?= MXjTRW5ITVJ?
NB69 NX[2VVFKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwN{i0Olkh|ryP NFTjeI9USU6JRWK=
NCI-H292 NGTQcmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlL0TWM2OD1zLki2Olk6KM7:TR?= M{T1RnNCVkeHUh?=
LOXIMVI Mnz6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfVTWM2OD1zLki5OFI4KM7:TR?= M{PpTnNCVkeHUh?=
BPH-1 M{n4e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3XIeWlEPTB;MT64PVU6OSEQvF2= MYjTRW5ITVJ?
A375 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXTcIp4UUN3ME2xMlg6PzF2IN88US=> MmnCV2FPT0WU
LCLC-97TM1 M13nPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTmTWM2OD1zLkmyNlU3KM7:TR?= NVTWXo1MW0GQR1XS
RXF393 M{joUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTFwOUe4PFch|ryP MXzTRW5ITVJ?
HCC70 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MknYTWM2OD1{LkCyOFI3KM7:TR?= NXTpOYlJW0GQR1XS
EM-2 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVuyXpFCUUN3ME2yMlA4OTl6IN88US=> NXv5V4pmW0GQR1XS
MZ2-MEL NYT0dlNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXuxbVZKUUN3ME2yMlEyOTJ5IN88US=> MlHHV2FPT0WU
HN MlTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\pN2lEPTB;Mj6xOlI4QCEQvF2= NHv0W|dUSU6JRWK=
A2058 MlXtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkTVTWM2OD1{LkG5Nlc6KM7:TR?= M{\mbXNCVkeHUh?=
NB7 Mlj1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV3JR|UxRTJwM{SwPFYh|ryP NELkW4pUSU6JRWK=
DOK NUDEe3VWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVXJR|UxRTJwM{W3O|Mh|ryP MVfTRW5ITVJ?
CAL-27 NIPyTmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4DhZWlEPTB;Mj6zPVI{PiEQvF2= MULTRW5ITVJ?
BB65-RCC MmPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnoWIZsUUN3ME2yMlQxPjd2IN88US=> MUnTRW5ITVJ?
RD MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1u5cGlEPTB;Mj60OFczOyEQvF2= Mm\jV2FPT0WU
KNS-62 Mk\NS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWnJR|UxRTJwNUGxOlQh|ryP NHPTN5BUSU6JRWK=
EW-13 NXPQeGVYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzPTWM2OD1{LkW2N|M6KM7:TR?= NVLUd2ppW0GQR1XS
DB NYTPb4ZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXPTWM2OD1{LkW4O|g5KM7:TR?= M4nRb3NCVkeHUh?=
HCC2218 NVqw[osxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmrxTWM2OD1{Lk[0O|c5KM7:TR?= MoLKV2FPT0WU
L-363 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX7PboYxUUN3ME2yMlc1OzdizszN NUHBZYZCW0GQR1XS
CHL-1 NHm2elRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mo\BTWM2OD1{LkiwO|g2KM7:TR?= M13Pe3NCVkeHUh?=
BFTC-905 MkO0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnVTWM2OD1{LkiyOVMh|ryP Moq0V2FPT0WU
HCE-T MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m3U2lEPTB;Mj64N|I3PCEQvF2= Ml3jV2FPT0WU
COLO-792 NEf0[nZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NU\LVZhzUUN3ME2yMlg1ODJ5IN88US=> M16zdXNCVkeHUh?=
LB2241-RCC Mln1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1zvdmlEPTB;Mj64OVg6OyEQvF2= NXfsNWhvW0GQR1XS
CAL-39 Mlv0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mny0TWM2OD1{Lki5PVk6KM7:TR?= MYHTRW5ITVJ?
T-24 MlW5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHO4fWxKSzVyPUKuPVEyOTJizszN MoXBV2FPT0WU
NCI-H727 Mn;BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTJwOUG3PVYh|ryP Ml2wV2FPT0WU
Ca9-22 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYriVIZvUUN3ME2yMlk4OjV3IN88US=> MoL6V2FPT0WU
MIA-PaCa-2 NXiyWYQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NITBb3lKSzVyPUOuNFA4QDFizszN NHHiPI1USU6JRWK=
HT-1080 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDkV2FKSzVyPUOuNFE6QTdizszN M2roOnNCVkeHUh?=
D-423MG NGHJcWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTNwMEe3OVMh|ryP MVnTRW5ITVJ?
LAMA-84 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGjBRlhKSzVyPUOuNVM2QCEQvF2= MUTTRW5ITVJ?
SW780 M{PPRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH;tRYRKSzVyPUOuNVQzOjlizszN NX\GS5pvW0GQR1XS
KU-19-19 NYrQdmtOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmL3TWM2OD1|LkG3NFM1KM7:TR?= MYjTRW5ITVJ?
COLO-741 Mn7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2TwNWlEPTB;Mz6xPFY4OyEQvF2= M3\lNXNCVkeHUh?=
HSC-3 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEfWcnRKSzVyPUOuNlMyPTFizszN M3;1d3NCVkeHUh?=
SN12C MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXzTWM2OD1|LkK0O|AyKM7:TR?= M3ruT3NCVkeHUh?=
786-0 MoLVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fPRWlEPTB;Mz6yO|I1OyEQvF2= MWLTRW5ITVJ?
GAK MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYi4O4pDUUN3ME2zMlMzPTZzIN88US=> MlzxV2FPT0WU
PANC-03-27 NX\uNnRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1r3cGlEPTB;Mz6zOVA1PSEQvF2= NV20XZlbW0GQR1XS
CTB-1 NEjFRoJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3riV2lEPTB;Mz60O|A1PyEQvF2= Mlv1V2FPT0WU
A427 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1m0eWlEPTB;Mz61PVU2PiEQvF2= MmnEV2FPT0WU
EGI-1 Mn7CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTNwNkC1PFMh|ryP M4jyW3NCVkeHUh?=
U-2-OS MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHeyWnhKSzVyPUOuOlczPTZizszN MomyV2FPT0WU
NCI-SNU-5 Mkf2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4XiZWlEPTB;Mz62O|c{KM7:TR?= Mn;MV2FPT0WU
SK-LU-1 Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1f3TGlEPTB;Mz62PFc6QCEQvF2= M3XYUnNCVkeHUh?=
697 M4X4bmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPlTWM2OD1|Lk[5OlA{KM7:TR?= NHX1TGZUSU6JRWK=
HPAF-II NVrDSFk1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PNcmlEPTB;Mz63OVQ6KM7:TR?= NEDVZpZUSU6JRWK=
NCI-H2087 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTNwOES2O|Ih|ryP M4nYRnNCVkeHUh?=
SK-MEL-3 M1LRUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGXWZ3RKSzVyPUOuPFUyPTRizszN NFTPdGxUSU6JRWK=
CGTH-W-1 NGjyUIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTNwOEW3NlUh|ryP NY\jRYFwW0GQR1XS
8505C MoHGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGDGenpKSzVyPUOuPVAxPzhizszN NGnJWGtUSU6JRWK=
GAMG NEK5OlRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTRwMEKzO|ch|ryP NYDEO25zW0GQR1XS
SW626 NFPkXmhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH:zU5dKSzVyPUSuNFQ1QCEQvF2= M3LxSHNCVkeHUh?=
CAL-62 NX;yUIZtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYftN|N4UUN3ME20MlA4PDNizszN MUnTRW5ITVJ?
MHH-PREB-1 NWroSmRNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjhSYVFUUN3ME20MlEzOTFzIN88US=> MknMV2FPT0WU
RPMI-7951 M13ZdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTRwMkW1PFkh|ryP MVfTRW5ITVJ?
HOP-92 NUHxOJlHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF\MbHVKSzVyPUSuNlU3PyEQvF2= NXHJNmlQW0GQR1XS
MDA-MB-231 NIT1b21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEPkfFRKSzVyPUSuNlkzOjNizszN MnnUV2FPT0WU
LAN-6 NX:4U|BuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MknmTWM2OD12LkOxOlM4KM7:TR?= MVPTRW5ITVJ?
ALL-PO NYfMU49[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTRwM{[xOVYh|ryP M{GyZnNCVkeHUh?=
HH MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkTsTWM2OD12LkSxOVk4KM7:TR?= NIDNNGdUSU6JRWK=
IGROV-1 MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTRwNEWxO|Eh|ryP NYLie5NrW0GQR1XS
NCI-H358 NETMOJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULrWWR{UUN3ME20MlQ2Ozh3IN88US=> MWXTRW5ITVJ?
NB5 NG[yUoRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljaTWM2OD12Lk[wN|Y6KM7:TR?= MofxV2FPT0WU
NCI-H747 MmHJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRTRwNki4NFch|ryP NHzBd3lUSU6JRWK=
NH-12 MkP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2n6cmlEPTB;ND63NVYzPSEQvF2= MV\TRW5ITVJ?
LB1047-RCC MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHJPVRCUUN3ME20Mlc{QDF3IN88US=> MYXTRW5ITVJ?
EFO-27 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nsbmlEPTB;ND63PFY3PyEQvF2= NUPBPYF[W0GQR1XS
EPLC-272H MljxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;BTWM2OD12Lkm5OlY6KM7:TR?= NXnieZo{W0GQR1XS
CAL-54 Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7sPVZKSzVyPUWuNFI3QTVizszN NY\MRZdXW0GQR1XS
H4 MoDQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTm[W1GUUN3ME21MlA1OjV3IN88US=> MlfMV2FPT0WU
MOLT-13 NVTJdJNJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzCV4FKSzVyPUWuNFY4PzZizszN M3H0[HNCVkeHUh?=
CAL-33 MnXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIew[YdKSzVyPUWuNVI{OTdizszN MU\TRW5ITVJ?
23132-87 M3uzcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGC5bVhKSzVyPUWuNVY5PzJizszN Ml;IV2FPT0WU
UM-UC-3 NF\rfGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHXTWM2OD13LkG4NFQ4KM7:TR?= NH;FSWpUSU6JRWK=
HuH-7 MlL6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4[2NWlEPTB;NT6yO|E1PyEQvF2= MkLMV2FPT0WU
BCPAP NHv2PWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTVwM{K5Olkh|ryP MXTTRW5ITVJ?
AsPC-1 M{WwW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n0bmlEPTB;NT6zOlc3OyEQvF2= MUTTRW5ITVJ?
NCI-H1155 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\tW2lEPTB;NT60NFA2OSEQvF2= NXTsPHZJW0GQR1XS
GT3TKB NX3UTnRmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYjJR|UxRTVwNE[1PVgh|ryP NULC[5l{W0GQR1XS
HCC2998 NFPsSHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn5U4hEUUN3ME21MlQ6OTB7IN88US=> M3nWT3NCVkeHUh?=
NUGC-3 NVvqT|M3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4q5TGlEPTB;NT60PVMxOiEQvF2= NIixe4lUSU6JRWK=
Hs-578-T NVPJdmpmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTVwNUO3PVQh|ryP NU[0PG5TW0GQR1XS
FADU NUDJeWdST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3jnVGlEPTB;NT61OVczPiEQvF2= M1nwTHNCVkeHUh?=
NBsusSR MoXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDa[WlKSzVyPUWuOVcyPTVizszN NGTpRpFUSU6JRWK=
ME-180 NFLU[3RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFHOXGlKSzVyPUWuOVgxQTJizszN MVvTRW5ITVJ?
SW1710 M3HRb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NI\xdHVKSzVyPUWuOlE3PTRizszN NV7ESYxGW0GQR1XS
HuP-T3 M3nYVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYHJR|UxRTVwNkKwNlkh|ryP NIPhVIpUSU6JRWK=
HOS M{HQOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLzWW5xUUN3ME21MlYzQTJ|IN88US=> MkPBV2FPT0WU
PA-1 NV63PYFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoDxTWM2OD13Lk[0NlY2KM7:TR?= MYLTRW5ITVJ?
LU-99A NInnT|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rBU2lEPTB;NT62OlQ2OSEQvF2= NUHsd2JuW0GQR1XS
RS4-11 M1vs[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYTJR|UxRTVwNk[3O|Uh|ryP MnXNV2FPT0WU
TE-8 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIexd3hKSzVyPUWuOlg2OzdizszN MW\TRW5ITVJ?
RERF-LC-MS Mme5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTFTWM2OD13Lk[4PFA{KM7:TR?= M3vVenNCVkeHUh?=
MEL-JUSO NGq5RW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYf1bnBlUUN3ME21Mlc{PzhizszN NFnxR2lUSU6JRWK=
SK-MES-1 NWW0b2tVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\ObWpXUUN3ME21Mlg{PTJ6IN88US=> NU[xW5E2W0GQR1XS
D-263MG M2rGcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1f4N2lEPTB;NT64PFM2OSEQvF2= MmrzV2FPT0WU
NB10 Ml\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGf3TY9KSzVyPUWuPFk1PiEQvF2= MW\TRW5ITVJ?
SK-HEP-1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnPDTWM2OD13LkmzOFcyKM7:TR?= NXzvcoY2W0GQR1XS
HT-29 MlHsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnYc3RsUUN3ME21Mlk5OTF6IN88US=> NYnaOWxGW0GQR1XS
KYSE-140 NVHCcWtsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGrYcplKSzVyPU[uNFIyQDJizszN NHG3Z5pUSU6JRWK=
NCI-H1666 NUPrfYtiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXm5bGFjUUN3ME22MlA5PDZzIN88US=> MWHTRW5ITVJ?
NCI-H1304 M3PJU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\1TWM2OD14LkG5PVQh|ryP NFvHbHNUSU6JRWK=
RPMI-8866 MnmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\NXmlEPTB;Nj6yNVMyOyEQvF2= MYnTRW5ITVJ?
MV-4-11 NYr0doRpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTZwMkOxPVkh|ryP NEXRTWxUSU6JRWK=
A431 NHHyfGdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTZwMkSyPVYh|ryP NFfzZWhUSU6JRWK=
PANC-10-05 M{DIZmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\ZTWM2OD14LkK4N|Y{KM7:TR?= M1jkXnNCVkeHUh?=
TK10 M3qzOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3EOZV2UUN3ME22MlMzPjB2IN88US=> M1nlNHNCVkeHUh?=
NCI-H1975 M{TLR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWXYNohMUUN3ME22MlQ4OjF3IN88US=> NYG5UlJYW0GQR1XS
A172 NVvIc4oyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrzTWM2OD14LkS5NVc3KM7:TR?= MmO1V2FPT0WU
D-566MG M3TJOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1fhTWlEPTB;Nj61OFMxOyEQvF2= MkPWV2FPT0WU
NCI-H2122 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrhV5dKSzVyPU[uOlE2OjhizszN MmrlV2FPT0WU
COR-L105 NVPjTFA3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\a[GlEPTB;Nj62OVI4PSEQvF2= Mki4V2FPT0WU
AN3-CA MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjNUZdKSzVyPU[uOlg3PDFizszN NH3aW5VUSU6JRWK=
Calu-6 NEnx[FRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmWxTWM2OD14Lke5Olk5KM7:TR?= NIPWOG9USU6JRWK=
HCT-116 NXPhVpNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLmU2FKSzVyPU[uPFEzPjRizszN NWPSfppoW0GQR1XS
MHH-NB-11 MoHZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUDJR|UxRTZwOEWwNFIh|ryP NH3qdHZUSU6JRWK=
MFE-280 M4TD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTZwOEW5PFMh|ryP NW[xPWpYW0GQR1XS
SW1088 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoH3TWM2OD14LkmxPVE{KM7:TR?= M17ERnNCVkeHUh?=
SW48 MnXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX70VVV4UUN3ME22Mlk1PTFizszN M3;YS3NCVkeHUh?=
HuCCT1 MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nsbGlEPTB;Nz6wNVA{PyEQvF2= MlO5V2FPT0WU
ACHN MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHf1fmFKSzVyPUeuNFI6PDNizszN M1e3OHNCVkeHUh?=
8305C NYT4SJp5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVHoSpNRUUN3ME23MlA6QTl3IN88US=> MljJV2FPT0WU
DoTc2-4510 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3vBVmlEPTB;Nz6xNlE2KM7:TR?= MWXTRW5ITVJ?
COR-L23 MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFWzfW9KSzVyPUeuNlQ1OiEQvF2= NWTDcYx{W0GQR1XS
SK-MEL-30 M{nE[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2\KbmlEPTB;Nz6yOVA5OyEQvF2= M1WzR3NCVkeHUh?=
BE-13 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrKSmtNUUN3ME23MlM{QDN2IN88US=> NXHXZXVVW0GQR1XS
GR-ST NHjnZnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEj2PY5KSzVyPUeuOFAyPzRizszN MnLtV2FPT0WU
LU-135 MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXyNpJKSzVyPUeuOVU6OzlizszN M{Hoe3NCVkeHUh?=
U-266 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEDE[ZhKSzVyPUeuOVYzQDZizszN MYLTRW5ITVJ?
NCI-H1355 MlnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1r1SWlEPTB;Nz61PFY{PSEQvF2= NXr2bmVLW0GQR1XS
NB14 NGDSfo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWS0TnRKUUN3ME23MlY3PjR{IN88US=> MlrEV2FPT0WU
SCC-25 MmrKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPZOnJKSzVyPUeuO|A6KM7:TR?= M3jwVnNCVkeHUh?=
COLO-678 MmHhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml\qTWM2OD15LkexNFc3KM7:TR?= MX7TRW5ITVJ?
TGBC1TKB NUPYTXo3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\hbGlEPTB;Nz64PVM6QCEQvF2= NWPuZ|V6W0GQR1XS
IST-MEL1 NVn6TZdLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4DhW2lEPTB;OD6wNFQxPiEQvF2= MWTTRW5ITVJ?
ECC10 NWPUXXJ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmSxTWM2OD16LkCzN|k2KM7:TR?= M4fvO3NCVkeHUh?=
EW-16 Mn3FS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRThwMEi0OFUh|ryP NFO2c|NUSU6JRWK=
DOHH-2 Mm\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVvMNpE{UUN3ME24MlIxODl3IN88US=> NYLhO4IyW0GQR1XS
NCI-H1581 NYryWmFVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWW3OYtkUUN3ME24MlI3OzJ|IN88US=> NX3v[4tXW0GQR1XS
TE-5 NE\CfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoT1TWM2OD16LkSyOFI6KM7:TR?= Ml3hV2FPT0WU
CAKI-1 MnzkS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MW\JR|UxRThwNUeyNlIh|ryP M33mWHNCVkeHUh?=
A673 M2jIUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nqT2lEPTB;OD62N|IxOiEQvF2= M2nEcXNCVkeHUh?=
CAL-12T M4TZ[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHHTWM2OD16Lk[1O|U{KM7:TR?= NF\QUlFUSU6JRWK=
DBTRG-05MG NFPpfXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MU\JR|UxRThwN{S4OVkh|ryP NVm2UohQW0GQR1XS
SK-N-FI MnW0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnmxTWM2OD16LkixN|c6KM7:TR?= MnroV2FPT0WU
K-562 Mli2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHiVXV1UUN3ME24Mlg{QTV5IN88US=> NX\jcIRKW0GQR1XS
SBC-1 Mn\VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXS0dmdzUUN3ME24Mlg3PjR3IN88US=> NWT5WGZGW0GQR1XS
ES4 M2TSU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoLmTWM2OD16Lki2PFg1KM7:TR?= NIfoSVFUSU6JRWK=
MS-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPuTWM2OD16Lki3OVE4KM7:TR?= Mn[xV2FPT0WU
RKO MlzXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2jPW2lEPTB;OD64PVA2PyEQvF2= NXq0bXpMW0GQR1XS
NCI-H1693 NWrqPYdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV31XW5LUUN3ME24MlkzOTdizszN M1L3TnNCVkeHUh?=
SW954 NVr6b3JkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{G3UWlEPTB;OD65Olk4QCEQvF2= NGm3NnVUSU6JRWK=
SK-UT-1 NYPsR5F4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2joRmlEPTB;OD65O|Y5OyEQvF2= Mn\kV2FPT0WU
T98G M4Pjfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLaWYVlUUN3ME24Mlk6QDR4IN88US=> M4TDSHNCVkeHUh?=
NCI-H2126 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTlwMEC4NlYh|ryP M4nYb3NCVkeHUh?=
TE-12 NVLoT2tsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlzLTWM2OD17LkCzN|Y4KM7:TR?= MVnTRW5ITVJ?
DK-MG M3fvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXETWM2OD17LkKxNVkyKM7:TR?= NUjQ[oFLW0GQR1XS
MEG-01 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mm\zTWM2OD17LkK0PVMyKM7:TR?= NUL1NnJpW0GQR1XS
HCC1937 MlXUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYPyOYczUUN3ME25MlI6ODlzIN88US=> NVnrOpBMW0GQR1XS
MKN45 MnzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33LeGlEPTB;OT60OVA3PSEQvF2= NFXsbJNUSU6JRWK=
NCI-H1792 NHvsT2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGHxRnRKSzVyPUmuOFUzOTlizszN NYqzdYZtW0GQR1XS
SW1417 NYXqd5RNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTlwNU[4N|ch|ryP MnnEV2FPT0WU
639-V NHPYb4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIDTOVJKSzVyPUmuOlQ{QDhizszN MWDTRW5ITVJ?
P30-OHK NUfreJF[T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mk\nTWM2OD17Lk[1N|E3KM7:TR?= MmC0V2FPT0WU
YKG-1 M3fvUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3RdXd1UUN3ME25Mlc2ODN|IN88US=> NWr4[2tJW0GQR1XS
KGN MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTlwOEO3PVUh|ryP NInNcXFUSU6JRWK=
MSTO-211H MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfuRXpKSzVyPUmuPVU2OjlizszN NWroWXgxW0GQR1XS
NCI-H1573 NGLwZVZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHDTWM2OD1zMD6xOVc1KM7:TR?= NV7TNI4{W0GQR1XS
NCI-H720 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFyLkG5PFkh|ryP NGrCUZBUSU6JRWK=
KARPAS-45 NILIU2RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLpXoRsUUN3ME2xNE4zPzl3IN88US=> MXnTRW5ITVJ?
MDA-MB-175-VII M2LQPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGL0ZmFKSzVyPUGwMlQ5KM7:TR?= NWjQR45GW0GQR1XS
SK-NEP-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYjJR|UxRTFyLkS5PFEh|ryP M2G2VnNCVkeHUh?=
MKN28 M2fEc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjjd2tKSzVyPUGwMlUyQCEQvF2= MmS1V2FPT0WU
KYSE-520 MlPYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFyLkWyJO69VQ>? MkXvV2FPT0WU
KE-37 M{\nNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLVTWM2OD1zMD61NlczKM7:TR?= NV62PHhYW0GQR1XS
VA-ES-BJ MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTFyLkW2O{DPxE1? MnTsV2FPT0WU
CCRF-CEM M17wcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUPSSplqUUN3ME2xNE42Pjh2IN88US=> MV;TRW5ITVJ?
GMS-10 NFPV[XZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWHJR|UxRTFyLk[wPVQh|ryP NIGwO4JUSU6JRWK=
NCI-H1623 MoqyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYTJR|UxRTFyLk[zO|kh|ryP NVjKTJBzW0GQR1XS
NEC8 NVr3c4loT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUjxfGZUUUN3ME2xNE44Pzd|IN88US=> MYDTRW5ITVJ?
MOLT-16 MnznS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NInFZ3RKSzVyPUGwMlgyOTNizszN NGPxNoJUSU6JRWK=
DJM-1 NG\yTHpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGnoNWNKSzVyPUGxMlA{PzlizszN NFrHZ2RUSU6JRWK=
U251 MmfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjrXVZxUUN3ME2xNU4xPDJizszN MUXTRW5ITVJ?
SBC-5 M4HRfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVqxWlQ3UUN3ME2xNU4yPDZ5IN88US=> NV7PVlBKW0GQR1XS
SW756 M3f0Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY\5PHlVUUN3ME2xNU4zOTV2IN88US=> MXPTRW5ITVJ?
KS-1 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPzUI46UUN3ME2xNU4zPjF7IN88US=> MXnTRW5ITVJ?
SF295 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIGweotKSzVyPUGxMlMyODRizszN Ml3iV2FPT0WU
YH-13 Mo\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTFzLkOyOlch|ryP NV;ZUYU1W0GQR1XS
SW837 NX;0Zpk2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jINGlEPTB;MUGuN|UxPiEQvF2= NFHlcJFUSU6JRWK=
KYSE-450 NELBcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkjJTWM2OD1zMT60NFU4KM7:TR?= NHPnXnNUSU6JRWK=
KYSE-180 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTFzLkS4NkDPxE1? MmXSV2FPT0WU
S-117 MnO1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnpcVFKSzVyPUGxMlQ5QTZizszN MX3TRW5ITVJ?
KOSC-2 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NG\pcWpKSzVyPUGxMlYzOjJizszN M3vSfHNCVkeHUh?=
KYSE-270 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV3JR|UxRTFzLki3OFUh|ryP M37Ue3NCVkeHUh?=
D-336MG NXz1dphmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;VbXhJUUN3ME2xNU46ODd3IN88US=> MlfWV2FPT0WU
KALS-1 NYC5NIdGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV;GS3BYUUN3ME2xNk4xODF4IN88US=> NXHnS41HW0GQR1XS
LB373-MEL-D NXq5XmtXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlPUTWM2OD1zMj6wOVM{KM7:TR?= MVnTRW5ITVJ?
HLE M4D2XGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{n5V2lEPTB;MUKuNFU5PSEQvF2= NH3wc3hUSU6JRWK=
SJSA-1 NHL5epBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTF{LkC3N|Uh|ryP M{f2OHNCVkeHUh?=
SW1990 NYPTOmtNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3npVGlEPTB;MUKuNFkyOSEQvF2= MWrTRW5ITVJ?
NOS-1 NWHxZWFNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnrmTWM2OD1zMj6xN|UzKM7:TR?= M{[1[nNCVkeHUh?=
GI-ME-N MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzkTnhKSzVyPUGyMlIyPjNizszN NWCxbW0{W0GQR1XS
NCI-H1703 MoXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTF{LkK2NVYh|ryP M1ewcXNCVkeHUh?=
ES7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjNTWM2OD1zMj6yO|I1KM7:TR?= M2LkZXNCVkeHUh?=
KYSE-510 Mmi1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUXJR|UxRTF{LkWwO|kh|ryP MlnQV2FPT0WU
BHY NXn5TGhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1i0WGlEPTB;MUKuOVMxPyEQvF2= NF7KVYFUSU6JRWK=
TCCSUP M2fYV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTF{LkW3OVch|ryP MlvIV2FPT0WU
HSC-2 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXxTWM2OD1zMj61PVk3KM7:TR?= Ml7rV2FPT0WU
BEN NFLMS4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;VTWM2OD1zMj62NVQ{KM7:TR?= M3XIdXNCVkeHUh?=
769-P NGPwU2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3rFPGlEPTB;MUKuO|kzPCEQvF2= MlzXV2FPT0WU
HT M3WycWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPqTWM2OD1zMj64N|Q3KM7:TR?= MVTTRW5ITVJ?
LXF-289 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;ye2lEPTB;MUKuPVU{OSEQvF2= MYHTRW5ITVJ?
OVCAR-3 NWHZPZJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGL6VWNKSzVyPUGyMlk2PjdizszN MYXTRW5ITVJ?
ATN-1 MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEWzPFFKSzVyPUGzMlAyQDRizszN MWLTRW5ITVJ?
8-MG-BA NXfCd4s4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYntSGFIUUN3ME2xN{4xPDV3IN88US=> MXXTRW5ITVJ?
SW13 MlS5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYLHVHM4UUN3ME2xN{4yOTZ3IN88US=> MYLTRW5ITVJ?
NCI-H1092 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjmTWM2OD1zMz6xOlIh|ryP NGjOWlJUSU6JRWK=
OAW-42 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fre2lEPTB;MUOuNVk{PyEQvF2= MUHTRW5ITVJ?
NCI-H2452 MkC1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LjW2lEPTB;MUOuNlE4PSEQvF2= NHH3WWZUSU6JRWK=
CAPAN-1 M17wXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTF|LkW1NVQh|ryP NIrSUHZUSU6JRWK=
NCI-H2009 NIW4Xo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYXJR|UxRTF|LkW5NVkh|ryP NIHtbpFUSU6JRWK=
SF268 NVfYU2RHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTF|Lk[zNlYh|ryP NELx[JZUSU6JRWK=
GCIY NYK2R4g{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPjN2lKSzVyPUGzMlY6OjdizszN MlzOV2FPT0WU
OS-RC-2 MmDzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVLJR|UxRTF|Lkm1NFEh|ryP MnS5V2FPT0WU
GCT MlX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7XVmxKSzVyPUGzMlk3QTdizszN MmX5V2FPT0WU
NB17 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3POR2lEPTB;MUSuNFg2KM7:TR?= MV7TRW5ITVJ?
NCI-H2030 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjzTWtKSzVyPUG0MlE1PjVizszN MljoV2FPT0WU
HC-1 M3izOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTF2LkKwPFch|ryP NY\S[WttW0GQR1XS
QIMR-WIL NUW1NFhJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1nJd2lEPTB;MUSuN|QyOiEQvF2= M4n3XHNCVkeHUh?=
Capan-2 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEHjbWdKSzVyPUG0MlM4OTRizszN NGrPOIVUSU6JRWK=
BALL-1 Mmm4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTF2LkS2OlUh|ryP MVrTRW5ITVJ?
LS-1034 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmTITWM2OD1zND62NVUzKM7:TR?= NHnzR2pUSU6JRWK=
U-118-MG NV\qfGNNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHrpUXNKSzVyPUG0MlY{OSEQvF2= NXq0SJpiW0GQR1XS
NCI-H630 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{i4eWlEPTB;MUSuOlU3QCEQvF2= MlWyV2FPT0WU
OVCAR-8 NHH0UGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnqbos{UUN3ME2xOE44OjBzIN88US=> NYrN[GFnW0GQR1XS
NCI-H2347 MkjLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnKyTWM2OD1zND64NlMh|ryP M2XOTnNCVkeHUh?=
BT-549 M3i3[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV7Eb5JsUUN3ME2xOE45Ojh2IN88US=> MnXtV2FPT0WU
LB831-BLC MmLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3f2c2lEPTB;MUSuPFk{PCEQvF2= Mne1V2FPT0WU
NCI-H661 NH;SUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlfhTWM2OD1zND65OVkh|ryP NXjEeXkzW0GQR1XS
MKN7 MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTF3LkCwPVMh|ryP M3XGVnNCVkeHUh?=
U-87-MG M{nQ[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HieWlEPTB;MUWuNFg6PyEQvF2= MXfTRW5ITVJ?
OVCAR-4 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTF3LkG0NlQh|ryP MlK5V2FPT0WU
OE33 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFP1SJRKSzVyPUG1MlE4OTFizszN MYXTRW5ITVJ?
EC-GI-10 M4LZU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWLJR|UxRTF3LkKzOVch|ryP MVHTRW5ITVJ?
AM-38 NVT0eZdxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmLvTWM2OD1zNT6yO|E4KM7:TR?= MojVV2FPT0WU
NCI-H1563 NIHodYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NULQXHJ6UUN3ME2xOU4{PDlizszN NXzZW2dOW0GQR1XS
SCC-4 NFnLc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2r0fmlEPTB;MUWuOFExOyEQvF2= M4\PVnNCVkeHUh?=
Detroit562 M3S2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH7TNJpKSzVyPUG1MlQ2PDdizszN NWHaVYpDW0GQR1XS
PC-14 M1j1Nmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzpTWM2OD1zNT60PFY3KM7:TR?= NFXJb3NUSU6JRWK=
ES3 Mo[xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTF3LkWzOkDPxE1? NF2zPHBUSU6JRWK=
OCI-AML2 MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M333TWlEPTB;MUWuO|YyPCEQvF2= MVHTRW5ITVJ?
LU-134-A NVH5TpNXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HHOWlEPTB;MUWuPVAyQCEQvF2= MUDTRW5ITVJ?
SAS MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3;KWmlEPTB;MUWuPVM4OyEQvF2= M4fKNHNCVkeHUh?=
TGBC11TKB MlvBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm0TWM2OD1zNT65OFE1KM7:TR?= NWDKeHhIW0GQR1XS
HOP-62 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2TxeWlEPTB;MUWuPVU6PyEQvF2= NIDlXIVUSU6JRWK=
G-401 NXuwOWJrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH\5cXVKSzVyPUG1Mlk3PDlizszN MmHDV2FPT0WU
NCI-H28 MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;oTWM2OD1zNj6wPFU3KM7:TR?= M3r3ZXNCVkeHUh?=
A204 M4LrOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\2TWM2OD1zNj6yNFA3KM7:TR?= MkDSV2FPT0WU
NCI-H1299 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1fDeWlEPTB;MU[uNlI6OSEQvF2= NV;yVHg4W0GQR1XS
VMRC-RCZ M3fE[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfnTWM2OD1zNj6yOVkzKM7:TR?= NFXmN|FUSU6JRWK=
BxPC-3 MoHjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NY\kblBLUUN3ME2xOk4zQDV4IN88US=> MXPTRW5ITVJ?
NCI-H2228 Mom2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2fRfGlEPTB;MU[uOVE2QCEQvF2= M3P1U3NCVkeHUh?=
NCI-H23 NY\3T5ZmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDxTWM2OD1zNj62NFc5KM7:TR?= M1XCVnNCVkeHUh?=
NKM-1 M1rJPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzJTWM2OD1zNz6wNVg6KM7:TR?= M1Pme3NCVkeHUh?=
KYSE-70 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXGwV|FqUUN3ME2xO{4zQDlizszN MnnKV2FPT0WU
BB49-HNC MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NY\ycIZHUUN3ME2xO{42Pjh4IN88US=> NYDVXotiW0GQR1XS
SCC-15 M1f1SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTF5Lki0O|Mh|ryP M1vJN3NCVkeHUh?=
D-247MG MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjDcYhKSzVyPUG3MlkzPDdizszN MX3TRW5ITVJ?
BB30-HNC M4\pTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV\JR|UxRTF6LkCzNVgh|ryP NWfF[ZNjW0GQR1XS
CAL-85-1 NV7B[2g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYrJR|UxRTF6LkG4NFkh|ryP NFryWm1USU6JRWK=
HT-3 NXK3XGNuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVLWRW8{UUN3ME2xPE4{QTd5IN88US=> M1z5VnNCVkeHUh?=
KYSE-410 NVG0[|Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NW\qcHRqUUN3ME2xPE41PTd5IN88US=> MVrTRW5ITVJ?
SW982 M2\LNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3:0S2lEPTB;MUiuOVY1QSEQvF2= NHTNeIFUSU6JRWK=
SW962 NWTUdpRtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnGwTWM2OD1zOD61O|AzKM7:TR?= NYnQZ5MyW0GQR1XS
Ramos-2G6-4C10 NHrtdlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NE\BV|RKSzVyPUG4MlU6OjdizszN MXTTRW5ITVJ?
OC-314 NIPjdlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF6LkezPFQh|ryP MmPtV2FPT0WU
LS-123 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn\iTWM2OD1zOD63PVAyKM7:TR?= NIjqcVJUSU6JRWK=
D-502MG NUOxdVEyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnnZTWM2OD1zOD64NVM6KM7:TR?= MUjTRW5ITVJ?
RO82-W-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3kbVNKSzVyPUG4MlgzQDhizszN M2rLZnNCVkeHUh?=
HuO9 NEXqS21Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TmWWlEPTB;MUmuNVM4QSEQvF2= NXHRe3NCW0GQR1XS
ETK-1 M{T1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTF7LkG4Nlch|ryP NFTUco9USU6JRWK=
SNU-387 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoXCTWM2OD1zOT6xPFg6KM7:TR?= MXLTRW5ITVJ?
SW1573 NV;0UI5xT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF7LkG5Olkh|ryP NGG0WpJUSU6JRWK=
NTERA-S-cl-D1 NFrkdWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVqwenNyUUN3ME2xPU4zODB5IN88US=> NV3FTZl7W0GQR1XS
SF126 M1\aSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M17VfWlEPTB;MUmuN|UxOiEQvF2= MWfTRW5ITVJ?
Calu-3 NWnySHg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MoTMTWM2OD1zOT60NlM4KM7:TR?= NUDHTXJTW0GQR1XS
NCI-H1048 MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF7LTnVKSzVyPUKwMlMzPjZizszN M4XiSXNCVkeHUh?=
NCI-H226 MlTDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn:wTWM2OD1{MD60N|k6KM7:TR?= MYPTRW5ITVJ?
FTC-133 NUCwcolET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnsXYdKSzVyPUKwMlQ4ODNizszN NVm5WGJQW0GQR1XS
SF539 M{TiVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHKTWM2OD1{MD61NVczKM7:TR?= M2HqR3NCVkeHUh?=
TE-6 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M37oemlEPTB;MkCuPFA3PyEQvF2= NFX0WGlUSU6JRWK=
UMC-11 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4j3cGlEPTB;MkCuPVE3PCEQvF2= M2K1VHNCVkeHUh?=
Becker NXnHN3dLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NF[1WZhKSzVyPUKxMlEyOThizszN MlPqV2FPT0WU
KP-4 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnHDTWM2OD1{MT6xNVk3KM7:TR?= M33sdHNCVkeHUh?=
ChaGo-K-1 M{[zVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlPBTWM2OD1{MT6zOlI4KM7:TR?= MUjTRW5ITVJ?
CFPAC-1 M3HWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjET2RKSzVyPUKxMlM5PThizszN NFTiXVBUSU6JRWK=
A498 MmexS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFLVdFdKSzVyPUKxMlU{OTJizszN M130[HNCVkeHUh?=
NCI-H1755 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYPJR|UxRTJzLk[3OFEh|ryP MUDTRW5ITVJ?
TI-73 NYrqfZFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NY\WN3Z3UUN3ME2yNk4{OjhizszN MWTTRW5ITVJ?
NCI-H441 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2fESWlEPTB;MkKuOVY5QSEQvF2= NUX2ZnRIW0GQR1XS
CaR-1 NV3mU3F5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELsN5lKSzVyPUKzMlAzOTNizszN MnKzV2FPT0WU
HCC1806 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrZelBpUUN3ME2yN{4xPTh|IN88US=> MWXTRW5ITVJ?
SNU-449 NE\xUXdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NITwOo5KSzVyPUKzMlMzQSEQvF2= NHvNcHZUSU6JRWK=
EKVX M1HSdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV3CN4p5UUN3ME2yN{4{QTB7IN88US=> MXvTRW5ITVJ?
DMS-114 Moe5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;PTWM2OD1{Mz61O|Y2KM7:TR?= M1PZZXNCVkeHUh?=
A704 M2\3bGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1H4c2lEPTB;MkOuOlExOyEQvF2= MVvTRW5ITVJ?
LC-2-ad MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkT1TWM2OD1{Mz62NVQ4KM7:TR?= NEHHUZBUSU6JRWK=
VM-CUB-1 M1P1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTJ|LkezOFEh|ryP MV7TRW5ITVJ?
PC-3 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWnJR|UxRTJ2LkC1NlYh|ryP MV7TRW5ITVJ?
HEL NFfLOnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHy3cm5KSzVyPUK0MlA5PjVizszN M4TxeHNCVkeHUh?=
ABC-1 NV;KNWdjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\FXGlEPTB;MkSuNlczQSEQvF2= NFPwPWtUSU6JRWK=
COLO-680N MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn;ZTWM2OD1{ND60O|Y1KM7:TR?= M3jK[HNCVkeHUh?=
MZ1-PC NYHuW4xRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGe2OZJKSzVyPUK0MlY5PyEQvF2= MonpV2FPT0WU
NCI-H69 NFTVSWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\1bWlEPTB;MkSuO|M2PCEQvF2= MYDTRW5ITVJ?
TE-1 M4ftW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGjBVVZKSzVyPUK1MlA1QTlizszN NWL1dGwxW0GQR1XS
EW-3 NU\mWo9FT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTJ3LkGxN{DPxE1? NEm0SVBUSU6JRWK=
PANC-08-13 NFzRU|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEDpUJZKSzVyPUK1MlgyODNizszN Mn[3V2FPT0WU
NMC-G1 NHrQWndIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGXTd3ZKSzVyPUK2MlAxQDhizszN NWjyNVF5W0GQR1XS
BT-20 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MluyTWM2OD1{Nj60OVQ{KM7:TR?= MmG2V2FPT0WU
TGBC24TKB M4PxSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1HU[WlEPTB;Mk[uO|M{OSEQvF2= NXPFWmhUW0GQR1XS
TE-11 M3LiXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoD1TWM2OD1{Nj65PFk2KM7:TR?= NX3qOG5kW0GQR1XS
ESS-1 NF7KXJNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFexcoZKSzVyPUK3MlMzOTZizszN MUDTRW5ITVJ?
JVM-3 NXPwWZlyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYfTOpB3UUN3ME2yO{43PDd3IN88US=> MUnTRW5ITVJ?
C3A NYG1fWwyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2PP[WlEPTB;MkeuPFQ6PiEQvF2= NGfkW|hUSU6JRWK=
MDA-MB-157 M170TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjBNIRXUUN3ME2yO{45PzV|IN88US=> NFLJNG5USU6JRWK=
KLE NVf5VlBRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LOTGlEPTB;MkiuNVA2QCEQvF2= NGrKNWpUSU6JRWK=
ES1 M2HtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGX6[odKSzVyPUK4MlE5OzhizszN MUfTRW5ITVJ?
CAL-120 M3vLPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVzGN3hGUUN3ME2yPE4{QTl7IN88US=> NGrCcpNUSU6JRWK=
NCI-N87 NEHEOpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTJ6LkWxNFUh|ryP M125bHNCVkeHUh?=
RPMI-8226 NWC2T|dvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXrJR|UxRTJ7LkG4OFMh|ryP NGHU[IFUSU6JRWK=
COR-L88 NVvSWXBKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYnJR|UxRTJ7LkK0NVkh|ryP M1WxfnNCVkeHUh?=
UACC-893 NYLiU5VmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX\3UlREUUN3ME2yPU4{OTN5IN88US=> NGL5O3VUSU6JRWK=
C8166 MoX4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXfJR|UxRTJ7Lkm5PVYh|ryP NH;DXG9USU6JRWK=
J82 M{L3Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrsbJRZUUN3ME2zNE45OTR5IN88US=> NETpeo5USU6JRWK=
PFSK-1 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHnFXGVKSzVyPUOxMlA3PTlizszN MnixV2FPT0WU
COLO-684 MoLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYXoVIRbUUN3ME2zNU41Ozd2IN88US=> MXPTRW5ITVJ?
CAL-72 NWPodnN3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmfOTWM2OD1|MT61O|I6KM7:TR?= M1\YfnNCVkeHUh?=
SNB75 NYP3b3lbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2DPfWlEPTB;M{GuPFk4KM7:TR?= MmTGV2FPT0WU
MDA-MB-415 MmSzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTNzLkm3OlIh|ryP NF\WNG5USU6JRWK=
SiHa M1PoSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEfVOXRKSzVyPUOyMlQ4OTFizszN NViwXoZkW0GQR1XS
NCI-H1648 NEXtPVVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX:z[WV7UUN3ME2zNk46OzR3IN88US=> MlWzV2FPT0WU
EFO-21 M2jqRmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVrJR|UxRTN|LkCwOUDPxE1? MYXTRW5ITVJ?
HCC38 M3TyeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm1TWM2OD1|Mz6zPFQyKM7:TR?= MnXIV2FPT0WU
IA-LM MkX5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LncGlEPTB;M{OuO|g5QSEQvF2= MYLTRW5ITVJ?
CTV-1 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnS1TWM2OD1|Mz65O|g3KM7:TR?= MkHBV2FPT0WU
NCI-H446 MnzVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYL0ZWlWUUN3ME2zOE4zPjh7IN88US=> M3fPV3NCVkeHUh?=
IST-SL1 M2XyRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;5V2lEPTB;M{SuO|QxQCEQvF2= M2LCTHNCVkeHUh?=
EW-22 NF3aSXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\pOJRFUUN3ME2zOE44PzV7IN88US=> M2nTN3NCVkeHUh?=
JEG-3 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jsN2lEPTB;M{[uNVc3PiEQvF2= MmK4V2FPT0WU
LU-65 MnH1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml61TWM2OD1|Nj6yPVg2KM7:TR?= NHfZS|FUSU6JRWK=
NCI-H596 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nBemlEPTB;M{[uPVU6OSEQvF2= NHnYOJFUSU6JRWK=
KNS-81-FD MorPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHGVnZoUUN3ME2zO{4yPDVizszN MX;TRW5ITVJ?
NCI-H1793 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTN5LkewPFYh|ryP NIfBUI9USU6JRWK=
NCI-H460 NXLoV3JUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTN6LkC4O|Mh|ryP MYXTRW5ITVJ?
MPP-89 MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHXwSZpKSzVyPUO5MlU5QDZizszN NXjqNYliW0GQR1XS
D-542MG M3zTN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTN7Lki0N|Yh|ryP M3L1enNCVkeHUh?=
JAR MmHSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\5WWlEPTB;NECuOFcxPSEQvF2= NX3uWWR2W0GQR1XS
NCI-H209 M{nq[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG[y[JNKSzVyPUSwMlY4PyEQvF2= MmTRV2FPT0WU
G-402 M1X3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzGTWM2OD12MT6zPVk{KM7:TR?= NWOxWZJwW0GQR1XS
IST-MES1 NXH5NpRET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3XZ5duUUN3ME20Nk4yQTN3IN88US=> NIjRSXBUSU6JRWK=
Daoy MnfjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIDYN5NKSzVyPUSyMlU1PzFizszN MkfwV2FPT0WU
EW-11 NXfIT4k5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1TjTmlEPTB;NEOuNVIyOSEQvF2= MkC1V2FPT0WU
Saos-2 M3L6OWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTR|LkG1N|ch|ryP MXnTRW5ITVJ?
no-10 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVu3VHJXUUN3ME20N{4yPzB{IN88US=> NGjOe5ZUSU6JRWK=
HCC1395 NFzC[4VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfGXVZKSzVyPUSzMlQ3PDRizszN MWnTRW5ITVJ?
HCE-4 NHLGTXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXzMRZl2UUN3ME20N{44PjZ2IN88US=> NIfqbJpUSU6JRWK=
EW-1 MlrjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfHNmxKSzVyPUSzMlgxPDlizszN NE[5W2JUSU6JRWK=
OCUB-M NFvRVYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVXJR|UxRTR2LkO2N|gh|ryP MXPTRW5ITVJ?
IGR-1 NV;ZU|JFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTR2LkSxNVUh|ryP M4HVeHNCVkeHUh?=
NCI-H1838 NWTFcoI2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH75ZmhKSzVyPUS0MlQ{PDlizszN MX\TRW5ITVJ?
NCI-H2405 NWjPO3k4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTR2LkWzOEDPxE1? NXfr[2ZNW0GQR1XS
GB-1 NXruOGRTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTR2Lke0OlMh|ryP MoHBV2FPT0WU
MG-63 NUCxOoV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWXpZZJ1UUN3ME20Ok4xPjl4IN88US=> M2qwNXNCVkeHUh?=
KP-N-YN M1OySGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXX1bFF6UUN3ME20Ok41Pjd7IN88US=> M33kfHNCVkeHUh?=
no-11 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr5UYZpUUN3ME20O{4xOjR2IN88US=> M4fmOHNCVkeHUh?=
SW948 M1nWNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV7JR|UxRTR5LkOzO|ch|ryP NX\CXIY2W0GQR1XS
CAMA-1 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrhR4VKSzVyPUS3MlM1OzhizszN NHTpVWVUSU6JRWK=
HCC1187 M1qzVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTR5LkWxJO69VQ>? MmjBV2FPT0WU
D-392MG M4LBfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXnndmdbUUN3ME20O{43PTF4IN88US=> MVvTRW5ITVJ?
647-V M3rGOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MofNTWM2OD12OT6zOFE1KM7:TR?= M2TlbHNCVkeHUh?=

... Click to View More Cell Line Experimental Data

In vivo Oral dosing of CI-1040 impairs the growth of colon tumor xenografts of mouse and human with a wide dose range of 48-200 mg/kg per dose, but not of P388 leukemia. [1] CI-1040 inhibits the tumor xenografts from PTC cells carrying a BRAF mutation with 31.3% reduction, carrying the RET/PTC1 rearrangement with 47.5% reduction than in untreated (vehicle) mice after 3 weeks of oral administration (300 mg/kg/d). No toxic effects are observed in any mice when they are treated with CI-1040. [2] Transient exposure of mammary tumors to CI-1040 and UCN-01 causes tumor cell death in vivo and prolonged suppression of tumor regrowth. Combined treatment with CI-1040 (25 mg/kg) and UCN-01 (0.1-0.2 mg/kg) significantly reduces MDA-MB-231, and largely abolishs MCF7 tumor growth in implanted athymic mice, while either single treatment has no significant activity. The drug combination leads to profound tumor cell death which correlates with a reduction in the phosphorylation of ERK1/2 and the immuno-reactivity of Ki67 and of CD31. [5]

Protocol

Kinase Assay:

[2]

+ Expand

MEK1 Assay:

MAP kinase is activated after phosphorylation by MEK; the activated MAP kinase subsequently phosphorylates myelin basic protein (MBP).Incorporation of 32P into myelin basic protein (MBP) is assayed in the presence of glutathione S-transferase (GST) fusion proteins containing the 44-kDa MAPK (GST-MAPK) or the 45-kDa MEK (GST-MEK1). Assays are conducted in 50μL of 50 mM Tris, pH 7.4/10 mM MgCl2 /2 mM EGTA/10 μM [γ-32P]ATP containing 10 μg of GST-MEK1, 0.5 μg of GST-MAPK, and 40 μg of MBP. After incubation at 30°C for 15 minutes, reactions are stopped by addition of Laemmli SDS sample buffer. Phosphorylated MBP is resolved by SDS/10% PAGE. This screening effort leads to the discovery of several small-molecule inhibitors of MEK, i.e. CI-1040. Experiments assessing the order of addition shows that CI-1040 directly inhibits MEK1 with a 50% inhibitory concentration (IC50) of 17 nM, without affecting the activity of MAPK.
Cell Research:

[1]

+ Expand
  • Cell lines: Colon 26 carcinoma cells
  • Concentrations: 0.1-10 μM
  • Incubation Time: 24 hours
  • Method:

    Cells are planted seeded in T-75 cm 2 flasks and treated the next day for 24 hous with either DMSO or CI-1040. Single-cell suspensions are collected, and pellets are fixed in ice-cold ethanol (70%) for 30 minutes. After centrifugation of the samples, propidium iodide (50 μg/mL) and RNase (30 units/mL) are added to the pellets for 20 minutes at 37 °C. After filtration, samples are analyzed by flow cytometry.


    (Only for Reference)
Animal Research:

[3]

+ Expand
  • Animal Models: PTC cells in athymic mice
  • Formulation: Cremophor EL–95% ethanol (50:50) and dilutes with water
  • Dosages: 150 mg/kg
  • Administration: Orally twice daily
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 96 mg/mL (200.55 mM)
Ethanol 14 mg/mL (29.24 mM)
Water <1 mg/mL
In vivo 30% PEG400+0.5% Tween80+5% propylene glycol, pH 9 10 mg/mL

* 1 mg/ml means slightly soluble or insoluble.
* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 478.67
Formula

C17H14ClF2IN2O2

CAS No. 212631-79-3
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00033384 Completed Breast Cancer|Colorectal Cancer|Lung Cancer|Pancreatic Cancer University of Alabama at Birmingham|National Cancer Institute (NCI) February 2002 Phase 2
NCT00034827 Completed Colorectal Neoplasms|Breast Neoplasms|Carcinoma, Non-Small-Cell Lung|Pancreatic Neoplasms Pfizer January 2002 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

MEK Signaling Pathway Map

MEK Inhibitors with Unique Features

Related MEK Products

Tags: buy PD184352 (CI-1040) | PD184352 (CI-1040) supplier | purchase PD184352 (CI-1040) | PD184352 (CI-1040) cost | PD184352 (CI-1040) manufacturer | order PD184352 (CI-1040) | PD184352 (CI-1040) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID